Stock Market Reviews

Read and share opinions on CLYM (Climb Bio, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
  Nov 6, 2025
• Climb Bio to Present at Upcoming Investor Conferences
  Nov 3, 2025
• William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential
  Oct 31, 2025
• Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
  Oct 21, 2025
• Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
  Oct 17, 2025
• Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
  Oct 1, 2025
• Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
  Sep 29, 2025
• Is Climb Bio, Inc. (CLYM) Stock Outpacing Its Medical Peers This Year?
  Sep 11, 2025
• Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
  Sep 4, 2025
• UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
  Aug 25, 2025
• Climb Bio to Present at Upcoming September 2025 Investor Conferences
  Aug 25, 2025
• Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year?
  Aug 20, 2025
• Climb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutions
  Aug 17, 2025
• Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
  Aug 12, 2025
• Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
  Jun 18, 2025
• Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  May 19, 2025
• Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
  May 14, 2025